Capstone Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Capstone Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$249K	Sell	753 -8,165	-92%	-$2.78M	﹤0.01%	1439
2025 Q4	$3.55M	Buy	8,918 +7,687	+624%	+$3.4M	0.01%	452
2025 Q3	$561K	Buy	+1,231	New	+$501K	﹤0.01%	1309
2024 Q4	–	Sell	-1,653	Closed	-$455K	–	1831
2024 Q3	$455K	Buy	+1,653	New	+$430K	﹤0.01%	1243
2022 Q4	–	Sell	-4,400	Closed	-$881K	–	1505
2022 Q3	$881K	Buy	+4,400	New	+$839K	0.01%	1086
2016 Q2	–	Sell	-21,958	Closed	-$1.38M	–	680
2016 Q1	$1.38M	Buy	+21,958	New	+$1.46M	0.04%	250

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capstone Investment Advisors's ALNY Position: Q1 2026 in Review

Capstone Investment Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 92% in Q1 2026, selling an estimated $2.78M and leaving 753 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #1439.

Capstone Investment Advisors first reported a position in ALNY in Q1 2016 and has held it in 6 quarters since. The position peaked at $3.55M in Q4 2025. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Capstone Investment Advisors held 753 shares of Alnylam Pharmaceuticals worth $249K as of Q1 2026.
Capstone Investment Advisors sold 8,165 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $2.78M.
Alnylam Pharmaceuticals made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #1439 holding.
Capstone Investment Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2016 and has held it in 6 quarters since.
Capstone Investment Advisors's Alnylam Pharmaceuticals position peaked at $3.55M in Q4 2025.
789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.